ライフサイエンスコーパス: smallpox vaccine

1 esponse effects, using undiluted and diluted smallpox vaccine.

2 es suggest the feasibility of a multiprotein smallpox vaccine.

3 uraging result for this candidate attenuated smallpox vaccine.

4 ssfully revaccinated with diluted (<or=1:10) smallpox vaccine.

5 if they or their close contacts receive the smallpox vaccine.

6 viral neutralization and part of the Dryvax smallpox vaccine.

7 f 1056 healthy adults after a single dose of smallpox vaccine.

8 he polyclonal human antibody response to the smallpox vaccine.

9 Vaccinia virus is the smallpox vaccine.

10 ination and thus provide a safer alternative smallpox vaccine.

11 that this is a fundamental attribute of the smallpox vaccine.

12 ristic of the human antibody response to the smallpox vaccine.

13 wise to exclude the B5 protein from a future smallpox vaccine.

14 er primary immunization with Aventis Pasteur smallpox vaccine.

15 with a 1 : 5 dilution of the Aventis Pasteur smallpox vaccine.

16 on assay is required to evaluate alternative smallpox vaccines.

17 lanning the immunologic assessment of future smallpox vaccines.

18 us complications associated with traditional smallpox vaccines.

19 infections, and the side effects of existing smallpox vaccines.

20 od options for alternative second-generation smallpox vaccines.

21 rant further assessment as candidate subunit smallpox vaccines.

22 ell-mediated immune responses induced by new smallpox vaccines.

23 cal to the success of the next generation of smallpox vaccines.

24 The licensed smallpox vaccine, ACAM2000, is a cell culture derivative

25 o examine a possible association between the smallpox vaccine and postvaccination ischemic events, we

26 has led to the production and stockpiling of smallpox vaccine and the immunization of some healthcare

27 vax vaccine or 1 of 2 lots of Sanofi Pasteur smallpox vaccine and were evaluated for vaccination succ

28 n undiluted or a 1 : 5 or 1 : 10 dilution of smallpox vaccine and who subsequently were tested for pl

29 h for preclinical and clinical trials of new smallpox vaccines and for evaluation of therapeutic agen

30 provide a benchmark against which new, safer smallpox vaccines and residual immunity can be compared.

31 ings have implications for the design of new smallpox vaccines and the understanding of immune respon

32 ing made in smallpox laboratory diagnostics, smallpox vaccines, and antiviral medications.

33 conclude that the protection afforded by the smallpox vaccine anti-EV response is predominantly media

34 ry vaccine trials of diluted Aventis Pasteur smallpox vaccine (APSV) demonstrated that immunization "

35 ual immunity to smallpox and supplies of the smallpox vaccine are being reconstituted.

36 , and IL-6 immune responses after receipt of smallpox vaccine are genetically controlled by HLA genes

37 Smallpox vaccine, arguably the most effective vaccine in

38 Practicing physicians should be aware that smallpox vaccine-associated myopericarditis is a real en

39 Two independent clinical trials of the smallpox vaccine (Aventis Pasteur) were conducted in hea

40 We studied antibody targets in smallpox vaccine by developing potent neutralizing antib

41 Preclinical studies to date with subunit smallpox vaccine candidates, however, have been limited

42 None of the smallpox vaccines caused illness in this model, and all

43 and immunogenicity of the new cell-cultured smallpox vaccine (CCSV) to that of the calf-lymph derive

44 Smallpox vaccines containing vaccinia virus elicit stron

45 The smallpox vaccine Dryvax, a live vaccinia virus (VACV), p

46 The smallpox vaccine Dryvax, which consists of replication-c

47 ration as an alternative to the conventional smallpox vaccine Dryvax.

48 r had recently received a booster of current smallpox vaccine (Dryvax) but not in VV-naive donors.

49 stic alternatives to the currently available smallpox vaccine (Dryvax).

50 of the human humoral immune response to the smallpox vaccine (Dryvax).

51 als (n = 1071) who received a single dose of smallpox vaccine (Dryvax, Wyeth Laboratories) and examin

52 While the smallpox vaccine, Dryvax or Dryvax-derived ACAM2000, hol

53 Vaccination with the current smallpox vaccine, Dryvax, produces protective immunity b

54 There is renewed interest in use of smallpox vaccine due to the potential for a bioterrorist

55 ding of the central protective activities of smallpox vaccine-elicited antibodies in immunized humans

56 Vaccinia virus (VACV), the smallpox vaccine, encodes many proteins that subvert the

57 dual MHC-II-restricted vaccinia virus (VACV, smallpox vaccine) epitopes revealed that CD4(+) T cell h

58 MVA is a promising candidate as a safer smallpox vaccine, even for immunocompromised individuals

59 virus ankara (MVA), a candidate replacement smallpox vaccine, failed to induce responses to two of t

60 heightened the need to develop an effective smallpox vaccine for immunization of the general public.

61 several nations are developing stockpiles of smallpox vaccine for use in the event the disease is rei

62 study, we tested current and investigational smallpox vaccines for safety, induction of anti-OPXV ant

63 The results demonstrate that smallpox vaccine given by bifurcated needle induces stro

64 his study measured the ability of a standard smallpox vaccine, given by scarification (by bifurcated

65 n of Wyeth Dryvax vaccine and Sanofi Pasteur smallpox vaccine, given that the resulting morbidity sho

66 tion of smallpox, vaccination rates with the smallpox vaccine have significantly dropped.

67 omised individuals, a group for whom current smallpox vaccines have an unacceptable safety profile.

68 cells underwent 3-week-long expansion after smallpox vaccine immunization and displayed simple reexp

69 munospot assay [ELISPOT]) immune response to smallpox vaccine in 1076 immunized individuals.

70 ortion of individuals who should not receive smallpox vaccine in a preexposure vaccination campaign.

71 es regulating the humoral immune response to smallpox vaccine in both Caucasians and African American

72 This evaluation of different human smallpox vaccines in cynomolgus macaques helps to provid

73 model for the safety and efficacy testing of smallpox vaccines in pre- and postexposure vaccine testi

74 considering smallpox vaccination and better smallpox vaccines in the future.

75 e or cytokine receptor gene polymorphisms in smallpox vaccine-induced adaptive immunity.

76 IL18R1 and IL18 genetic loci for broad-based smallpox vaccine-induced adaptive immunity.

77 Our results demonstrate that variations in smallpox vaccine-induced cytokine responses are modulate

78 similarities of antigenic protein targets of smallpox vaccine-induced responses in humans and prairie

79 The mechanisms underlying smallpox vaccine-induced variations in immune responses

80 cinia virus (VACV), the virus comprising the smallpox vaccine, induces memory CD8(+) T cells that pro

81 APSV is an effective smallpox vaccine inducing strong humoral and cellular im

82 minated by vaccination; however, because the smallpox vaccine is a live orthopoxvirus vaccine (vaccin

83 The currently used smallpox vaccine is associated with a high incidence of

84 The smallpox vaccine is associated with more serious adverse

85 Smallpox vaccine is considered a gold standard of vaccin

86 Studying the immune protection mechanism of smallpox vaccine is important for understanding the basi

87 New information about smallpox vaccine is included in this year's review becau

88 le, and the development of a safer effective smallpox vaccine is necessary.

89 Moreover, the safety of the smallpox vaccine is of great concern, as complications m

90 The smallpox vaccine is the prototypic vaccine, yet the vira

91 One approach for a safer smallpox vaccine is to utilize recombinant subunits rath

92 The smallpox vaccine is widely considered the gold standard

93 Vaccinia virus, the basis of the smallpox vaccine, is one of the largest viruses to repli

94 onses upon vaccination, since its use as the smallpox vaccine led to the eradication of one of the wo

95 in IOC (VACV-IOC) was the seed strain of the smallpox vaccine manufactured by the major vaccine produ

96 enuated cell culture-adapted Lister vaccinia smallpox vaccine missing the B5R protein and licensed fo

97 etween HLA alleles and 15 immune outcomes to smallpox vaccine on a per-locus and a per-allele level.

98 Why this is the case and how the smallpox vaccine overcomes this challenge remain incompl

99 These properties, shared with the existing smallpox vaccine, provide a basis for further evaluation

100 Smallpox vaccine provided protection against both infect

101 Thus, the current smallpox vaccine provides long-lasting CD4 help that may

102 ntially lethal complication that develops in smallpox vaccine recipients with severely impaired cellu

103 es in mediating adaptive immune responses to smallpox vaccine remains unknown.

104 Vaccinia virus (VV), the virus smallpox vaccine, replicates in the cytoplasm of infecte

105 t 1 and 3-5 weeks after vaccination with the smallpox vaccine, serial measurements have not been perf

106 In this study, we demonstrate that smallpox vaccine-specific memory B cells last for >50 ye

107 To evaluate the humoral immune responses to smallpox-vaccine stocks currently available in the Unite

108 recent common ancestor, probably an ancient smallpox vaccine strain related to horsepox virus.

109 rization of two clones of VACV-IOC, a unique smallpox vaccine strain that contributed to smallpox era

110 ne (Wyeth/IL-15/PA) using the licensed Wyeth smallpox vaccine strain that is efficacious against both

111 Altogether, these data indicate the smallpox vaccine succeeds in generating strong neutraliz

112 Therefore, the development of safer smallpox vaccines that can match the immunogenicity and

113 Therefore, the search for new-generation smallpox vaccines that combine low pathogenicity, immune

114 virus strains, including the current clonal smallpox vaccine, that the ability of a strain to spread

115 us (VV) as a vector for other Ags and as the smallpox vaccine, there is little information available

116 nisations have identified the need for a new smallpox vaccine to replenish limited stocks of the appr

117 ast five years, and that there is not enough smallpox vaccine to vaccinate everyone in the United Sta

118 esponding to the live yellow fever virus and smallpox vaccines--two highly successful human vaccines.

119 The smallpox vaccine using vaccinia virus has been highly su

120 f protective humoral immunity induced by the smallpox vaccine (vaccinia virus [VACV]).

121 f the human anti-B5 antibody response to the smallpox vaccine (vaccinia virus) are heavily dependent

122 uate the potential to increase the supply of smallpox vaccine (vaccinia virus), we compared the respo

123 rsistent infections, influenza virus and the smallpox vaccine virus (vaccinia virus), were studied.

124 Smallpox vaccine was administered by scarification using

125 0 years ago as a highly attenuated candidate smallpox vaccine, was recloned from a 1974 passage and e

126 rison of responses to newly produced lots of smallpox vaccine, we evaluated dose-response effects, us

127 To develop a modern smallpox vaccine, we have adapted vaccinia virus that wa

128 igating the efficacy of various dilutions of smallpox vaccine, we observed the appearance of a papulo

129 antibody responses that are elicited by the smallpox vaccine, which has enabled the first eradicatio

130 Alternative smallpox vaccines with an improved safety profile would